Flazalone is an anti-inflammatory drug that has not been approved as a medicine. Further Analogues According to Shaomeng Wang and co-workers, replacement of the para-fluoro halogen with a meta,para-dichloro substitution arrangement resulted in dopamine reuptake inhibitors useful in treating cocaine addiction. Whereas Diclazalone achieved a Ki of 10.9nM for the mazindol binding site (DAT), flazalone only achieved 5700nM for the same receptor (even weaker than for the phenindamine precursor which was 4420nM). However, the para-methyl compound was the one titled in the article publications. This had a Ki of 492nM for the mazindol binding site (DAT), which is more promising than flazalone if we are only talking about this receptor. For comparison consider WIN 35,428 versus RTI-32.
Synthesis The synthesis has been covered: Patents:Daniel Draper Marshall, CH496700 & NL6811811 (1970 to Rexall Drug Chemical).M Draper & L Levy, (1974 to Riker Laboratories Inc). Alternate synthesis:Charles M Leir, (1975 to Riker Laboratories Inc). 62%:
N.B. The p-fluoroacetophenone [403-42-9] has dual use in the synthesis of Enecadin [259525-01-4].
See also Phenindamine References